On August 2, 2024, Oncolytics Biotech Inc. launched an at-the-market (ATM) offering valued at up to $50 million USD (approximately $69.23 million CAD based on the August 1 exchange rate of 1.3846 CAD/USD). The offering, facilitated through an Equity Distribution Agreement with Cantor Fitzgerald & Co., allowed Oncolytics to sell shares on Nasdaq under the ticker "ONCY," excluding Canadian exchanges per NI 44-102 guidelines. Cantor Fitzgerald earned a 3.0% commission on gross proceeds from each sale. Legal counsel for Oncolytics included McCarthy Tétrault LLP in Canada and Dorsey & Whitney LLP in the U.S., while Cantor was represented by Paul Hastings LLP. Proceeds were allocated to support clinical program advancements, general corporate activities, and administrative expenses. The offering's estimated expenses, excluding Cantor’s fees, totaled approximately $125,000 USD.